Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business
Strides Pharma Science Ltd · Investor Presentation · 30 Oct 2026, 12:27 am
Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business Strides Pharma Science posted Q2FY27 revenue of ₹14,297m, up 17.1% YoY, driven by Ex-US markets growing 31% YoY to ₹6,963m and surpassing US revenue (₹6,855m, up 9% YoY) for the first time. EBITDA rose 8.4% YoY to ₹2,509m with margins at 17.6% (-140 bps YoY) due to higher material and logistics costs. Operational PAT grew 11.5% YoY to ₹1,358m. Net debt increased by ₹2,114m in H1FY27 to ₹16,479m (1.72x EBITDA). Strides shifted its ~$375m US revenue goal beyond FY28 amid normalized oral solid opportunities and controlled substance quota constraints.
Original exchange filing (PDF)
More announcements from Strides Pharma Science Ltd
- Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 02 Nov 2026
- Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 2026 · 30 Oct 2026
- Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026. · 30 Oct 2026
- Allotment of Equity shares pursuant to exercise of Stock Options. · 30 Oct 2026
- Strides Delivers Strong Performance with Q2FY27 Revenue at Rs. 14.297m, Grew 17% YoY. Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to Rs. 2,509m, Crossing Rs. 2,500m in a Quarter for the First Time. · 30 Oct 2026
- Financial Results for the quarter and half year ended Sept 30, 2026 · 30 Oct 2026
- Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 30 Oct 2026
- Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 30 Oct 2026
